Improved outcomes in E2A::HLF positive B-cell acute lymphoblastic leukemia by chimeric antigen receptor T cell therapy and BCL-2 inhibitor

作     者：Shumin Chen Ye Li Zheng Wang Lin Feng Yueping Jia Xiaodong Mo Yu Wang Qian Jiang Xiaojun Huang Yueyun Lai Shumin Chen;Ye Li;Zheng Wang;Lin Feng;Yueping Jia;Xiaodong Mo;Yu Wang;Qian Jiang;Xiaojun Huang;Yueyun Lai

作者机构：Peking University Institute of HematologyPeking University People’s HospitalBeijing 100044China Department of PediatricsPeking University People’s HospitalBeijing 100044China Research Unit of Key Technique for Diagnosis and Treatments of Hematologic MalignanciesChinese Academy of Medical Sciences(2019RU029)Beijing 100044China 

出 版 物：《Chinese Medical Journal》 (中华医学杂志（英文版）)

年 卷 期：2023年第136卷第11期

页      面：1382-1384页

核心收录：

学科分类：1002[医学-临床医学] 100214[医学-肿瘤学] 10[医学] 

主　　题：HLF lymphoblastic acute 

摘      要：To the Editor:The fusion gene E2A::HLF(TCF3::HLF)is formed by t(17;19)(q21-22;p13),which presents in1%of B-cell acute lymphoblastic leukemia(B-ALL)and mainly occurs in older children and adolescents.[1]Such patients were often accompanied by drug resistance and early relapse,which confer an extremely poor prognosis,and even intensive chemotherapy and hematopoietic stem cell transplantation(HSCT)cannot improve their survival.[2]A few studies suggested that chimeric antigen receptor T(CAR-T)cell therapy or BCL-2 inhibitors might benefit such patients.